Nevanac Related Clinical Trials
Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema [Active, not recruiting]
Nepafenac 0.3% Two Study [Completed]
Confirmatory Study Nepafenac 0.3% [Completed]
Topical Nepafenac as Supplement for Diabetic Macular Edema [Completed]
Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% [Completed]
Effect of Topical Nepafenac in Macular Thickening Related to Pan-Retinal Photocoagulation [Recruiting]
A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification [Completed]
A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients [Completed]
Effect of Nepafenac Eye Drops on Intraocular Pressure in Normal Eyes [Completed]
Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT) [Completed]
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification [Completed]
Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification [Recruiting]
Macular Edema Incidence/Severity Reduction With Nevanac [Terminated]
Nevanac 3-Month Safety Study With QID Dosing [Completed]
Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery [Recruiting]
Topic Antiinflammatory Therapy Added to Selective Photocoagulation in Macular Edema [Completed]
Nepafenac Once Daily for Macular Edema - Study 2 [Completed]
Nepafenac Once Daily for Macular Edema - Study 1 [Completed]
Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK [Completed]
Nepafenac Compared to Placebo for Ocular Pain and Inflammation [Completed]
A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief [Completed]
Topical Treatment of Uveitic Macular Edema [Not yet recruiting]
Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo [Completed]
Anti-inflammatory Efficacy for Prophylaxis of Cystoid Macular Edema (CME) After Phacoemulsification [Completed]
Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery [Completed]
Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery [Completed]
Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy [Recruiting]
Prophylactic Nepafenac and Ketorolac Versus Placebo in Patients Undergoing Cataract Surgery [Completed]
Effect of Anti-inflammatory Topical Prednisolone, Nepafenac and Ketorolac in Intra-operative Mydriasis in Facetectomies [Active, not recruiting]
Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery [Completed]
Comparison of Diclofenac vs. Nepafenac Ophthalmic Drops: Patient Comfort [Recruiting]
Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery [Completed]
NSAIDs and PGE2 Levels in Vitrectomy Patients [Completed]
Dropless vs. Standard Drops Contralateral Eye Study [Recruiting]
Comparison of Pain Sensation During Single Use of Two Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) [Recruiting]
NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME) [Completed]
Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1% [Completed]
Therapeutic Variables in Cataract Surgery [Completed]
|